In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mersana Therapeutics Inc.

www.mersana.com

Latest From Mersana Therapeutics Inc.

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs

Mersana Axes Lead ADC Compound, Puts All Its Eggs In NaPi2b Basket

Mersana Therapeutics has discontinued its lead candidate because of the competitive landscape surrounding HER2-targeted therapies, and will refocus on its only other clinical program, the NaPi2b-targetting ADC XMT-1536 for ovarian cancer and NSCLC.

Cancer Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Nanopharma Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mersana Therapeutics Inc.
  • Senior Management
  • Anna Protopapas, Pres. & CEO
    David A Spellman, CFO
    Timothy B Lowinger, PhD, CSO
    Eva M Jack, CBO
  • Contact Info
  • Mersana Therapeutics Inc.
    Phone: (617) 498-0020
    840 Memorial Dr.
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register